Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Survodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zealand Pharma, demonstrated up to 19% weight loss after 46 weeks of treatment in a Phase II dose escalation trial investigating the drug in patients living with obesity without type 2 diabetes (T2D). In a statement announcing the plans, Boehringer Ingelheim said that insights from previous studies will be used to inform the design of the three Phase III trials which will investigate the efficacy and safety of survodutide. Enrolment of patients is planned before the end of 2023, with the company saying that study details will be unveiled nearer to trial commencement. Survodutide has previously received a US Food and Drug Administration (FDA) fast track designation ...
Boehringer Ingelheim has shared positive new 48-week data from a phase 2b trial of its anti-interleukin-36 receptor (IL-36R) antibody in patients with generalised pustular psoriasis (GPP). The results from the EFFISAYIL 2 trial, presented by the company at this year’s World Congress of Dermatology, show that spesolimab reduced the risk of GPP flares by 84% over 48 weeks compared to placebo. The trial also demonstrated no flares after week four of spesolimab treatment in the high dose group, Boehringer said. GPP is a rare and chronic neutrophilic skin disease, which is genetically and clinically distinct from plaque psoriasis. GPP is caused by neutrophils – a type of white blood cell – accumulating in the skin, causing painful, sterile pustules all over the body. Despite the varying severity of GPP flares, if left untreated they can be life-threatening due to complications such as sepsis and multisystem organ failure, and the unpredictability ...
Geisinger and Merck & Co. have developed two EHR based programs named MedTrue and the Family Caregiver to improve adherence to medications, help providers and patient care and reduce drug errors. As these two apps are entering into market they have become a popular discussion topic with a few health IT companies.
Boehringer Ingelheim is expanding its $77 million contract biologics China plant, making a notable bet that the kind of contract services it offers elsewhere will be a big draw to China too.
Blockchain technologies have devised a method to obtain a patient’s health records from a blockchain database even if they are unable to communicate. A verification from two different keys is needed for this step.
There are three instances of Epic along with three varied versions of Meditech, Athena health and Cerner. Lahey Health, Beth Israel Deaconess Medical Center along with three other hospitals, are currently involved in merging the organizations under one roof, as they are operating with varied EHR vendors and versions.
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Black Book found that one-third of practices with more than 11 clinicians are considering EHR replacement options within the next few years.
A recent survey of 300 primary care physicians who use EHRs found that half of the respondents wanted better access to patient data.
Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics, based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.